Catumaxomab

Catumaxomab
Monoclonal antibody
Type	Trifunctional antibody
Source	Rat/mouse hybrid
Target	EpCAM, CD3
Clinical data
Trade names	Removab
AHFS/Drugs.com	International Drug Names
License data	EU EMA: by INN;
Routes of; administration	intraperitoneal infusion
ATC code	L01FX03 (WHO) ;
Legal status
Legal status	In general: ℞ (Prescription only);
Identifiers
CAS Number	509077-98-9 ;
DrugBank	DB06607 ;
ChemSpider	none;
UNII	M2HPV837HO;
	(what is this?) (verify)

Catumaxomab^[1] (trade name Removab) is a rat-mouse hybrid monoclonal antibody which is used to treat malignant ascites, a condition occurring in people with metastasizing cancer. It binds to antigens CD3 and EpCAM. It was developed by Fresenius Biotech and Trion Pharma (Germany).